Skip to content

Paul C. Lorigan

University of Manchester

2 papers in the Anchorcite directory, published between 2010 and 2015, cited 21,435 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine · 2010 · 15,401 citations

    BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100)…

  2. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations

    BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…

Metadata from OpenAlex (CC0).